Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study

References

• Guo H, Wei J, Li X, et al. Do socioeconomic factors modify the effects of PM1 and SO2 on lung cancer incidence in China? Sci Total Environ. 2021;756:143998. doi:10.1016/j.scitotenv.2020.143998
   PubMed Web of Science ®Google Scholar
• Zhang J, Mao W, Chen Z, Gu H, Lian C. Clinical significance of Has_circ_0060937 in bone metastasis of NSCLC. Int J Gen Med. 2020;13:1115–1121. doi:10.2147/ijgm.s279023
   PubMed Web of Science ®Google Scholar
• Chen J, Chen J, Lv X, Yang Q, Yao S. Epidermal growth factor in exhaled breath condensate as diagnostic method for non-small cell lung cancer. Technol Cancer Res Treat. 2019;18:1533033819872271. doi:10.1177/1533033819872271
   Web of Science ®Google Scholar
• Jahanzeb M, Lin HM, Pan X, et al. Immunotherapy treatment patterns and outcomes among ALK-positive patients with non-small-cell lung cancer. Clin Lung Cancer. 2021;22(1):49–57. doi:10.1016/j.cllc.2020.08.003
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi:10.1056/nejm197111182852108
   PubMed Web of Science ®Google Scholar
• Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205–215. doi:10.1016/j.jtho.2020.10.006
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Blanco R, Maestu I, de la Torre MG, Cassinello A, Nuñez I. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26(3):451–463. doi:10.1093/annonc/mdu268
   PubMed Web of Science ®Google Scholar
• Wang S, Liang Q, Chi Y, et al. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. Thorac Cancer. 2020;11(5):1149–1159. doi:10.1111/1759-7714.13356
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Imai H, Minemura H, et al. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;85(4):761–771. doi:10.1007/s00280-020-04055-7
   PubMed Web of Science ®Google Scholar
• Alexa T, Antoniu SA, Alexa I, et al. Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. Expert Rev Anticancer Ther. 2021;21(3):315–323. doi:10.1080/14737140.2021.1852933
   PubMed Web of Science ®Google Scholar
• Zhong Y, Wei Q, Lu Y, et al. Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer. J Thorac Dis. 2020;12(10):6016–6022. doi:10.21037/jtd-20-2855
   PubMed Web of Science ®Google Scholar
• Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep. 2015;17(6):26. doi:10.1007/s11912-015-0448-y
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–529. doi:10.1016/s0140-6736(15)01088-0
   PubMed Web of Science ®Google Scholar
• Song PF, Xu N, Li Q. Efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage SCLC and the prognostic significance of common adverse reactions. Cancer Manag Res. 2020;12:11133–11143. doi:10.2147/cmar.s275624
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019;66:e27747. doi:10.1002/pbc.27747
   PubMed Web of Science ®Google Scholar
• Guo M, Li B, Yu Y, et al. Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: a SEER based analysis. Cancer Med. 2019;8(5):2587–2598. doi:10.1002/cam4.2127
   PubMed Web of Science ®Google Scholar
• Fukuda M, Soda H, Soejima Y, et al. A Phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2006;58(5):601–606. doi:10.1007/s00280-006-0188-7
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun N, Sun P, Zhang L. Clinical characteristics and prognosis of elderly small cell lung cancer patients complicated with hyponatremia: a retrospective analysis. Anticancer Res. 2017;37(8):4681–4686. doi:10.21873/anticanres.11872
   PubMed Web of Science ®Google Scholar
• Bongiolatti S, Mazzoni F, Gonfiotti A, et al. Short and mid-term outcomes of multimodal treatment for locally-advanced non-small cell lung cancer in elderly patients. Gen Thorac Cardiovasc Surg. 2020;68(11):1290–1297. doi:10.1007/s11748-020-01384-5
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626–4631. doi:10.1200/jco.2004.02.175
   PubMed Web of Science ®Google Scholar
• Brozos-Vázquez EM, Díaz-Peña R, García-González J, et al. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol Immunother. 2021;70(5):1177–1188. doi:10.1007/s00262-020-02752-z
   PubMed Web of Science ®Google Scholar
• Schulz C, Gandara D, Berardo CG, et al. Comparative efficacy of second- and subsequent-line treatments for metastatic NSCLC: a fractional polynomials network meta-analysis of cancer immunotherapies. Clin Lung Cancer. 2019;20(6):451–460.e455. doi:10.1016/j.cllc.2019.06.017
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–1219. doi:10.1111/cas.13536
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Q, Li L, et al. OA13.03 Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind Phase 2 trial. J Thorac Oncol. 2018;13(10):S351–S352. doi:10.1016/j.jtho.2018.08.308
   Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.ccr-17-3766
   PubMed Web of Science ®Google Scholar
• Li J, Chen P, Dai CH, Li XQ, Bao QL. Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study. Geriatr Gerontol Int. 2009;9(2):172–182. doi:10.1111/j.1447-0594.2009.00525.x
   PubMed Web of Science ®Google Scholar
• Hu W, Li B, Geng N, et al. Association between PDL1 genetic variation and efficacy of apatinib monotherapy in patients with previously treated advanced NSCLC: a real-world retrospective study. Int J Gen Med. 2021;14:2703–2714. doi:10.2147/ijgm.s303717
   PubMed Web of Science ®Google Scholar
• Geng N, Su J, Liu Z, et al. The influence of KDR genetic variation on the efficacy and safety of patients with advanced NSCLC receiving first-line bevacizumab plus chemotherapy regimen. Technol Cancer Res Treat. 2021;20:15330338211019433. doi:10.1177/15330338211019433
   Web of Science ®Google Scholar
• Zhang K, Ma X, Gao H, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study. Cancer Manag Res. 2020;12:3409–3417. doi:10.2147/cmar.s246000
   PubMed Web of Science ®Google Scholar
• Zhong Q, Liu Z. Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer: a real-world study. Cancer Manag Res. 2021;13:4115–4128. doi:10.2147/cmar.s304838
   PubMed Web of Science ®Google Scholar
• Cheng JD, Chai LX, Zhao ZP, Hao YY, Li S. Efficacy and safety of anlotinib for patients with advanced NSCLC who progressed after standard regimens and the preliminary analysis of an efficacy predictor. Cancer Manag Res. 2020;12:5641–5650. doi:10.2147/cmar.s253366
   PubMed Web of Science ®Google Scholar
• Wang P, Fang X, Yin T, et al. Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-A Retrospective Study. Front Oncol. 2021;11:628124. doi:10.3389/fonc.2021.628124
   PubMed Web of Science ®Google Scholar
• Wang J, Ma JJ, Liu J, et al. Prevalence and risk factors of comorbidities among hypertensive patients in China. Int J Med Sci. 2017;14(3):201–212. doi:10.7150/ijms.16974
   PubMed Web of Science ®Google Scholar
• Fang SC, Huang W, Zhang YM, Zhang HT, Xie WP. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. Onco Targets Ther. 2019;12:985–992. doi:10.2147/ott.s189984
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S, Wang Z, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10(1):153. doi:10.1186/s13045-017-0521-0
   PubMed Web of Science ®Google Scholar
• Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. Onco Targets Ther. 2018;11:7077–7087. doi:10.2147/ott.s169484
   PubMed Web of Science ®Google Scholar
• Tang JR, Markham NE, Lin YJ, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L344–L351. doi:10.1152/ajplung.00291.2003
   PubMed Web of Science ®Google Scholar
• Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927–934. doi:10.1093/annonc/mdm550
   PubMed Web of Science ®Google Scholar
• Oliveros E, Patel H, Kyung S, et al. Hypertension in older adults: assessment, management, and challenges. Clin Cardiol. 2020;43(2):99–107. doi:10.1002/clc.23303
   PubMed Web of Science ®Google Scholar